Boston Scientific Corporation (BSX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Company Performance - Boston Scientific achieved 16.5% organic growth and 22% EPS growth in 2024, with a strong start to 2025 showing 18% organic growth and 34% EPS growth in Q1 [3][4]. Strategic Focus - The company aims to maintain high execution standards and strives to be a leading medtech company, with a commitment to achieving this goal over the next five years [4].